Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 4
Submit an article Journal homepage
19
Views
17
CrossRef citations to date
0
Altmetric
Review

Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy

Patrick Willemot Royal Victoria Hospital, McGill University Health Center, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, USA. [email protected]
&
Marina B Klein McGill University Health Centre, Division of Infectious Diseases and Immunodeficiency Service, 3650 Saint Urbain, Montreal, Quebec H2X 2P4, USA. [email protected]
Pages 521-532 | Published online: 10 Jan 2014

References

  • Centers for Disease Control and Prevention. Pneumocystis pneumonia —Los Angeles. Morb. Mortal. Wkly Rep. 30(21), 250–252 (1981).
  • Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 12(1), 29–33 (1998).
  • Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl. J. Med. 338(13), 853–860 (1998).
  • •First major article showing population-wide improvement with the introduction of highly active antiretroviral therapy (HAART).
  • Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 13(14), 1933–1942 (1999).
  • San-Andres FJ, Rubio R, Castilla J, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989–1997. Clin. Infect. Dis. 36(9), 1177–1185 (2003).
  • Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. I. Infect. 42(2), 134–139 (2001).
  • Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa. Lancet 359(9323), 2059–2064 (2002).
  • •Compares incidences of tuberculosis inpatients with and without access to HAART as opposed to comparing incidences in different calendar year cohorts.
  • Miller V, Sabin CA, Phillips AN, et al. The impact of protease inhibitor-containing highly active antiretroviral therapy on the progression of HIV disease and its relationship to CD4 and viral load. AIDS 14(14), 2129–2136 (2000).
  • •Suggests that the benefits of HAART go beyond what can be explained by the usually quantified viral load and CD4 cell count, perhaps due to the qualitative redistribution of lymphocytes within the different subpopulation reservoirs.
  • McDonald AM, Li Y, Dore GJ, Ree H, Kaldor JM. Late HIV presentation among AIDS cases in Australia, 1992-2001. Aust. NZ J. Public Health 27,608–613 (2003).
  • Girardi E, Sampaolesi A, Gentile M, Nurra G, Ippolito G. Increasing proportion of late diagnosis of HIV infection among patients with AIDS in Italy following introduction of combination antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 25,71–76 (2000).
  • Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons — 2002. Morb. Mortal. Wkly Rep. Recomm. Rep. 51(RR-8), 1–52 (2002).
  • •Very thorough set of guidelines for the prevention of opportunistic infections.
  • Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystisjiroveci) for pneumocystis from humans. Emerg. Infect. Dis. 8(9), 891–896 (2002).
  • Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 61(1), 35–41 (1978).
  • Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 111(3), 223–231 (1989).
  • Phair J, Murioz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J. Med. 322(3), 161–165 (1990).
  • Tasci S, Ewig S, Burghard A, Luderitz B. Pneumocystis carinii pneumonia. Lancet 362(9378), 124 (2003).
  • Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis and drug treatment of Pneumocystis carinii pneumonia. J. Am. Med. Assoc. 286(19), 2450–2460 (2001).
  • Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. J. Am. Med. Assoc. 259(8), 1185–1189 (1988).
  • Antinori A, Murri R, Ammassari A, et al Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 9(12), 1343–1350 (1995).
  • Hardy WD, Feinberg J, Finkelstein DM, et al A controlled trial of trimethoprim—sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J. Med. 327(26), 1842–1848 (1992).
  • Schneider MME, Nielsen TL, Nelsing S, et al Efficacy and toxicity of two doses of trimethoprim—sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. J. Infect. Dis. 171(6), 1632–1636 (1995).
  • El-Sadr WM, Luskin-Hawk R, Yurik TM, et al A randomized trial of daily and thrice-weekly trimethoprim—sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Clin. Infect. Dis. 29(4), 775–783 (1999).
  • Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J. Infect. Dis. 180(2), 369–376 (1999).
  • Carr A, Tindall B, Penny R, Cooper DA. Trimethoprim—sulfamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS 6(2), 165–171 (1992).
  • Ena J, Amador C, Pasquau F, et al. Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clin. Infect. Dis. 18(6), 901–904 (1994).
  • Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim—sulfamethoxazole compared with dapsone—pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann. Intern. Med. 122(10), 755–761 (1995).
  • Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone—pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin. Infict. Dis. 20(3), 531–541 (1995).
  • El-Sadr WM, Murphy RE, Yurik TM, et al Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J. Med 339(26), 1889–1895 (1998).
  • Para MF, Finkelstein D, Becker S, Dohn M, Walawander A, Black JR Reduced toxicity with gradual initiation of trimethoprim—sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia. J Acquir. Immune Defic. Syndr. 24(4), 337–343 (2000).
  • Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim—sulfamethoxazole (TMP—SMZ). Clin. Infict. Dis. 20(4), 849–853 (1995).
  • •Practical approach to desensitizing patients within the context of an office-based practice.
  • Wallace MR, Rossetti RJ, Olson PE. Cats and toxoplasmosis risk in HIV-infected adults. J Am. Med Assoc. 269(1), 76–77 (1993).
  • Luft BJ, Hafner R, Korzun AH, et al Toxoplasmic encephalitis in patients with the acquired immunodeficicency syndrome. N Engl J Med 329(14), 995–1000 (1993).
  • Sacktor N, Lyles RH, Skolasky R, et al HIV-associated neurologic disease incidence changes. Neurology 56(2), 257–260 (2001).
  • Carr A, Tindall B, Brew BJ, et al Low-dose trimethoprim—sulfamethoxazole prophylaxis for toxoplasmic encephalitits in patients with AIDS. Ann. Intern. Med 117(2), 106–111 (1992).
  • Leport C, Chene G, Morlat P, et al Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection. J. Infict. Dis. 173(1), 91–97 (1996).
  • Katlama C, De Wit S, °Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine—clindamycin vs. pyrimethamine—sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin. Infict. Dis. 22(2), 268–275 (1996).
  • Podzamczer D, Mire JM, Bolao F, et al Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Ann. Intern. Med 123(3), 175–180 (1995).
  • Torres RA, Weinberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Clin. Infect. Dis. 24(3), 422–429 (1997).
  • Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J. Med. 324(19), 1332–1338 (1991).
  • Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J. Infect. Dis. 165(6), 1082–1085 (1992).
  • Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994–1998. Lancet 356 (9226), 291–296 (2000).
  • Oldfield EC 3rd, Fessel WJ, Dunne MW, et al. Once-weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS. Clin. Infect. Dis. 26(3), 611–619 (1998).
  • Hewitt RG, Papandonatos GD, Shelton MJ, et al. Prevention of disseminated Mycobacterium avium complex infection with reduced dose darithromycin in patients with advanced HIV disease. AIDS 13(11), 1367–1372 (1999).
  • Nightingale SD, Cameron DW, Gordin FM, et al Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J. Med. 329 (12) 828–833 (1993).
  • Moore RD, Chaisson RE. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 9(12), 1337–1342 (1995).
  • Selwyn PA, Hartel D, Lewis VA, et al A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J. Med. 320(9), 545–550 (1989).
  • Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 342(8866), 268–272 (1993).
  • Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk of developing tuberculosis among anergic patients infected with HIV. Ann. Intern. Med 119(3), 194–198 (1993).
  • Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. HIV and pulmonary tuberculosis: the impact goes beyond those infected with HIV. AIDS 18,657–662 (2004).
  • Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the USA among HIV-infected persons. Ann. Intern. Med. 126(2), 123–132 (1997).
  • Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J. Med. 337(12), 801–808 (1997).
  • Kirk O, Gatell JM, Mocroft A, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. Am. J. Respir. Crit. Care Med. 162(3 Pt 1), 865–872 (2000).
  • Halsey NA, Coberly JS, Desormeaux J, et al. Randomized trail of isoniazid versus rifampicin and pyrazinamide for the prevention of tuberculosis in HIV-1 infection. Lancet 351(9105), 786–792 (1998).
  • Gordin FM, Maus JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J. Med. 337(5), 315–320 (1997).
  • Cohn DL, O'Brien RJ. Targeted tuberculin testing and treatment of latent tuberculosis infection. Morb. Mortal Wkly Rep. 49(RR-6), 1–51 (2000).
  • Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons. J. Am. Med. Assoc. 283(11), 1445–1450 (2000).
  • ATS/CDC. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection — USA 2003. Morb. Mortal. Wkly Rep. 52(31), 735–739 (2003).
  • Spector SA, McKinley GF, Lalezari JP, et al. Oral gancidovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J. Med. 334(23) 1491–1497 (1996).
  • Drew WL, Ives D, Lalezari JP, et al. Oral gancidovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl. J. Med. 333(10), 615–620 (1995).
  • Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral gancidovir in persons infected with human immunodeficiency virus. J. Infect. Dis. 171(6), 1431–1437 (1995).
  • Lalezari J, Lindley J, Walmsley S, et al A safety study of oral valgancidovir maintenance treatment of cytomegalovirus retinitis. J. Acquir. Immune Defic. Syndr. 30(4), 392–400 (2002).
  • Martin DF, Sierra-Madero J, Walmsley S, et al A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J. Med. 346(15), 1119–1126 (2002).
  • Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of AIDS patients in Thailand, 1994–1998. Clin. Infect. Dis. 32(6), 955–962 (2001).
  • Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J. Med. 321(12), 794–799 (1989).
  • Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 104(2), 234–240 (1986).
  • Havlir DV, Dube MP, McCutchan A, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin. Infect. Dis. 27(6), 1369–1375 (1998).
  • McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection. Clin. Infect. Dis. 28(5), 1049–1056 (1999).
  • Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin. Infect. Dis. 34(2), 277–284 (2002).
  • Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 118(8), 610–616 (1993).
  • Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J. Med. 324(9), 580–584 (1991).
  • Powderly WG, Saag MS, Cloud GA, et al A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J. Med. 326(12), 793–798 (1992).
  • Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 28(2), 291–296 (1999).
  • Holmberg SD, Moorman AC, Von Bargen JC, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. J. Am. Med. Assoc. 279(5), 384–386 (1998).
  • Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients' Infect. Dis. 177(4), 1080–1083 (1998).
  • Jouan M, Saves M, Tubiana R, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 15(1), 23–31 (2001).
  • Lopez Bernardo de Qiros JC, Miro JM, Pella JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N Engl J. Med. 344(3), 159–167 (2001).
  • Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J. Med. 344(3), 167–174 (2001).
  • Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Lancet 355(9222), 2217–2218 (2000).
  • Currier JS, William PL, Koletar SL, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. Ann. Intern. Med. 133(7), 493–503 (2000).
  • Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance threrapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann. Intern. Med. 137(4), 239–250 (2002).
  • Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in-patients with AIDS-treated with highly active antiretroviral therapy: an international observational study. Clin. Infect. Dis. 38, 565–571 (2004).
  • Vibhagool A, Sung,kanuparph S, Mootsikapun P, et al Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly-active antiretroviral therapy. Clin. Infect. Dis. 36(10), 1329–1331 (2003).
  • Torriani FJ, Freeman WR, Macdonald JC, et al CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 14(2), 173–180 (2000).
  • Trikalinos TA, Ioannidis JPA. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 33(11), 1901–1909 (2001).
  • Goldie SJ, Kaplan JE, Losina E, et al Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia. Arch. Intern. Med 162(8), 921–928 (2002).
  • Fournier S, Rabian C, Alberti C, et al Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon — (production in the presence of Toxoplasma gondii antigens). J. Infect. Dis. 183(11),1586-1591 (2001).
  • Komanduri KV, Feinberg J, Hutchins RK, et al Loss of cytomegalovirus-specific CD4+ T-cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T-cell counts and recurrent retinitis. J. Infect. Dis. 183(8), 1285–1289 (2001).
  • Crothers K, Huang L. Recurrence of Pneumocystis carinii pneumonia in an HIV-infected patient. HIV Med 4(4), 346–349 (2003).
  • Furrer H, Opravil M, Rossi M, et al Discontinuation of primary prophylaxis in HIV-infected patients at risk of Pneumocystis carinii pneumonia. AIDS 15(4), 501–507 (2001).
  • Maiman M, Fruchter RG, Sedlis A, et al Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol 68(3), 233–239 (1998).
  • Minkoff H, Feldman J, DeHovitz J, Landesman S, Burk R A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am. J. Obstet. Gynecol 178(5), 982–986 (1998).
  • Ellerbrock TV, Chiasson MA, Bush TJ, et al Incidence of cervical squamous intraepithelial lesions in HIV-infected women. J. Am. Med Assoc. 283(8),1031-1037 (2000).
  • Heard I, Bergeron C, Jeannel D, Henrion R, Kazatchkine MD. Papanicolaou smears in human immunodeficiency virus-seropositive women during follow-up. Obstet. Gynecol. 86(5), 749–753 (1995).
  • Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin. Infect. Dis. 35(9), 1127–1134 (2002).
  • Schuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J. Infect. Dis. 188(1), 128–136 (2003).
  • Hankins C, Coutlee F, Lapointe N, et al. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Can. Med. Assoc. J. 160(2), 185–191 (1999).
  • Serraino D, Carrieri P, Pradier C, et al. Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int. J. Cancer 82(3), 334–337 (1999).
  • Melbye M, Cote TR, Kessler L, Gail M, Biggar RJ. High incidence of anal cancer among AIDS patients. Lancet 343(8898), 636–639 (1994).
  • Frisch M, Smith E, Grulich A, Johansen C. Cancer in a population-based cohort of men and women in registered homosexual partnerships. Am. J. EpidemioL 157,966–972 (2003).
  • Minkoff H, Ahdieh L, Massad LS, et al The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 15(16), 2157–2164 (2001).
  • Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection associated cervical disease in human immunodeficiency virus-infected women. J. Infect. Dis. 184(5), 547–551 (2001).
  • Palefsky JM. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr. Opin. Oncol. 15(5), 382–388 (2003).
  • Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann. Intern. Med. 130(2), 97–107 (1999).
  • Mai AL, Yim C, O'Rourke K, Heathcote EJ. The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men. J. Clin. Gastroenterol 22(4), 299–304 (1996).
  • Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol 26(1), 1–5 (1997).
  • Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection. Clin. Infect. Dis. 33(4), 562–569 (2001).
  • Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the human immunodeficiency virus Atlanta Veterans Affairs medical center Cohort Study (HAVACS). Clin. Infect. Dis. 29(1), 150–154 (1999).
  • Macias J, Melguizo I, Fernandez-Rivera FJ, et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected paients receving potent antiretroviral therapy. Eur. J. Clin. Microbial. Infect. Dis. 21(11), 775–781 (2002).
  • Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. J. Am. Med. Assoc. 286(23), 2981–2987 (2001).
  • Lori F, Maserati R, Foli A, Seminari E, Timpone J, Lisziewicz J. Structured treatment interruptions to control HIV. Lancet 355(9200), 287–288 (2000).
  • Lawrence J, Mayers DL, Huppler Hullsiek K, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl. J. Med. 349(9), 837–846 (2003).
  • DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann. Intern. Med. 133(6), 447–454 (2000).
  • Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophtalmol 125(3), 292–300 (1998).
  • Karavellas MB, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J. Infect. Dis. 179(3), 697–700 (1999).
  • Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 351(9098), 252–255 (1998).
  • Koval CE, Gigliotti F, Nevins D, Demeter LM. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus Type 1 infection. Clin. Infect. Dis. 35(4), 491–493 (2002).
  • Hoffman C, Horst HA, Albrecht H, Schlote W. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J. Neural. Neurosurg. Psychiatry 74(8), 1142–1144 (2003).
  • Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin. Infect. Dis. 35(12), 128–133 (2002).
  • Martinez E, Gatell J, Moran Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin. Infect. Dis. 27 (6), 1510–1513 (1998).
  • Navas E, Martin-Davila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch. Intern. Med. 162(1), 97–99 (2002).
  • Furrer H, Malinverni R. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. Am. J. Med. 106(3), 371–372 (1999).
  • Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus Type 1-infected patients with progressive multifocal leukoencephalopathy. Clin. Infect. Dis. 35(10), 1250–1257 (2002).
  • Blau N, Leaf HL, Wieczorek RE, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 349(9056), 924–925 (1997).
  • Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 349(9057), 995–996 (1997).
  • John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors. AIDS 12(17),2289-2293 (1998).
  • Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receving triple antiretroviral therapy. Clin. Infect. Dis. 27(5), 1255–1258 (1998).
  • Chung RT, Evans SR, Yang Y, et al Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects. AIDS 16(14), 1915–1923 (2002).
  • Sulowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J. Am. Med. Assoc. 283(1),74-80 (2000).

Websites

  • Panel on Clinical Practices for Treatment of HIV Infection, USA Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo.nih.gov. (Accessed July 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.